the Prevalence of Acute Kidney Injury in Patients With Chronic Hepatitis c Virus Receiving Sofuspovir Containing Direct Acting Antiviral Therapy
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Investigate the Renal Effect of DAAs on Egyption Patients After Completion of Treatment
- Sponsor
- Cairo University
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- investigate the renal injury which can be caused during using sofuspovir containing DAA regimen in HCV treatment
- Last Updated
- 6 years ago
Overview
Brief Summary
this study aims is to investigate the occurrence of AKI during antiviral therapy, defined as an increase of 0.3 mg/dL or 50% at least in serum creatinine level when compared with baseline values or more than a 25% reduction in (eGFR) when compared with baseline eGFR in Egyptian patients.In addition to evaluate the change in insulin resistance value after treating patients from HCV.
Detailed Description
There are limited published data, currently, suggesting the risk of AKI during oral direct acting antiviral treatment. Most case reports and retrospective studies reported the presence of an intrinsic cause of renal injury, with most of the available biopsies showing acute tubular necrosis (ATN) and acute interstitial nephritis (AIN). Most of these patients had returned to baseline renal function on cessation of sofosbuvir combination therapy. Recently it was found that a notable percentage of patients experienced a transient increase in creatinine during therapy, which could occasionally lead to a more than 50% decrease in patients' eGFR. Previous studies had also shown that the co-use of nonsteroidal anti-inflammatory drugs (NSAIDs) and recurrent ascites were at increased risk for AKI during sofosbuvir-based antiviral therapy. The primary endpoint of this study is to investigate the occurrence of AKI in Egyptian patients during antiviral therapy and to highlight its reasons and time of incidence in addition to the mechanism of this injury.
Investigators
Dalia K. Zaafar
lecturer of pharmacology
Cairo University
Eligibility Criteria
Inclusion Criteria
- •patients suffering from HCV
- •male or female
- •easy to treat naive patients
Exclusion Criteria
- •pregnant women
- •seffering from HBV
- •diffecult to treat
- •other comorbodities as heart diseases or COPD
Outcomes
Primary Outcomes
investigate the renal injury which can be caused during using sofuspovir containing DAA regimen in HCV treatment
Time Frame: from the start to 6 months later
to investigate effect of DAA on kidney of treated patients and the mechanism of the drug to cause this renal effect by causing renal buimarkers including NAG and eGFR
Secondary Outcomes
- highlight the effect of DAAs on insulin resistance in diabetic patients suffering from HCV(from the starting of treatment till the 3-months follow up after the end of the treatment regimen)